Ann: Intention to launch Share Purchase Plan, page-62

The presentation titled Combination Therapies: How do we get there from the recent PPMD conference identified key issues that resonated with discussions on ANP threads. One discussion of particular interest revolved around the decision making process in relation to the appropriateness of combination therapies. Doctors must take into consideration drug-drug interactions, how one drug might affect another drug both from the viewpoint of side effects as well as efficacy. For instance will the interaction of combination therapy lead to improved or diminished patient benefit.

The panel looked at the importance of the aggregation of data from different approved products without the expense of running combination trials. One of the panellists discussed the importance of data from animal models.

The panel discussion brought home the importance of the DMD combination therapy animal study combining ATL1102 with a dystrophin exon skipping restoration drug. Combination trials are the gold standard but firstly, they may be cost prohibitive and secondly time is precious.